AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
XOMA Royalty Completes Tender Offer for HilleVax, Acquiring 77.48% of Shares.
ByAinvest
Wednesday, Sep 17, 2025 9:08 am ET1min read
XOMA Royalty Corporation has successfully completed its tender offer to acquire all outstanding shares of HilleVax common stock for a price of $1.95 in cash, plus a non-tradeable contingent value right. A total of 39,214,689 shares were validly tendered, representing approximately 77.48% of the outstanding shares of HilleVax common stock. The transaction is expected to enhance XOMA Royalty's portfolio of biotechnology assets.
XOMA Royalty Corporation has successfully completed its tender offer to acquire all outstanding shares of HilleVax common stock for a price of $1.95 in cash, plus a non-tradeable contingent value right. A total of 39,214,689 shares were validly tendered, representing approximately 77.48% of the outstanding shares of HilleVax common stock. The transaction is expected to enhance XOMA Royalty's portfolio of biotechnology assets [1].The acquisition was announced on September 12, 2025, and the tender offer period commenced on April 15, 2025. The offer was made by XOMA Royalty Corporation, and the dealings and positions in the offeror were not required to be disclosed [1].
The transaction is subject to customary closing conditions, including the receipt of necessary regulatory approvals. The completion of the acquisition is expected to provide XOMA Royalty Corporation with access to HilleVax's proprietary technology and intellectual property, further strengthening its position in the biotechnology sector.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet